Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 19/20 | 0.69 |
| ▸ | CASP7 | P55210 | 15/20 | 0.69 |
| ▸ | CASP1 | P29466 | 8/20 | 0.69 |
| ▸ | CASP9 | P55211 | 6/20 | 0.69 |
| ▸ | CASP4 | P49662 | 3/20 | 0.55 |
| ▸ | CASP10 | Q92851 | 3/20 | 0.54 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.54 |
| ▸ | CASP5 | P51878 | 1/20 | 0.54 |
| ▸ | CASP6 | P55212 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4461379 | 0.96 | CASP3 (0.64) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL15939366 | 0.96 | CASP3 (0.64) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL2038060 | 0.93 | CASP3 (0.63) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL2039051 | 0.91 | CASP3 (0.69) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL7168373 | 0.91 | CASP1 (0.58) | CASP3CASP7CASP1CASP9 | |
| SCHEMBL4952116 | 0.91 | CASP3 (0.60) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL2043662 | 0.90 | CASP3 (0.56) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL29362585 | 0.89 | CASP3 (0.76) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL2040978 | 0.88 | CASP3 (0.57) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL17326941 | 0.88 | CASP3 (0.72) | CASP3CASP7CASP1CASP9CASP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030105046-A1 | Interleukin converting enzyme (ICE) and central nervous system damage | THE GENERAL HOSPITAL CORPORATION | 2003-06-05 | — | — | US | claimed |
| WO-1998057664-A9 | INTERLEUKIN CONVERTING ENZYME (ICE) AND CENTRAL NERVOUS SYSTEM DAMAGE | YUAN JUNYING (US) | 1999-04-08 | — | — | WO | claimed |
| WO-1998057664-A1 | INTERLEUKIN CONVERTING ENZYME (ICE) AND CENTRAL NERVOUS SYSTEM DAMAGE | THE GENERAL HOSPITAL CORPORATION (US) | 1998-12-23 | — | — | WO | claimed |
| EP-3296390-B1 | METHOD FOR PRODUCING STEM CELL CLONES SUITABLE FOR INDUCTION OF DIFFERENTIATION INTO SOMATIC CELLS | UNIV KYOTO (JP) | 2023-01-04 | — | — | EP | disclosed |
| US-20210062158-A1 | Method for Producing Stem Cell Clones Suitable for Induction of Differentiation into Somatic Cells | UNIV KYOTO (JP) | 2021-03-04 | — | — | US | disclosed |
| US-10799552-B2 | Methods for treating diabetic neurotherapy | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2020-10-13 | — | — | US | disclosed |
| EP-2560629-B1 | METHODS AND COMPOSITIONS FOR PRESERVING PHOTORECEPTOR AND RETINAL PIGMENT EPITHELIAL CELLS | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2020-06-03 | — | — | EP | disclosed |
| US-10639345-B2 | Compositions for preserving photoreceptor cells, retinal pigment epithelial cells, or visual function | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2020-05-05 | — | — | US | disclosed |
| US-10617735-B2 | Methods and compositions for preserving retinal ganglion cells | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2020-04-14 | — | — | US | disclosed |
| US-20190216881-A1 | METHODS AND COMPOSITIONS FOR PRESERVING PHOTORECEPTOR AND RETINAL PIGMENT EPITHELIAL CELLS | MASSACHUSETTS EYE AND EAR INFIRMARY | 2019-07-18 | — | — | US | disclosed |
| US-20190117724-A1 | METHODS FOR TREATING SPINAL CORD INJURY | CHILDREN'S MEDICAL CENTER CORPORATION | 2019-04-25 | — | — | US | disclosed |
| US-20070287756-A1 | Methods and Compositions for Preserving the Viability of Photoreceptor Cells | MASSACHUSETTS EYE AND EAR INFIRMARY | 2007-12-13 | — | — | US | disclosed |
| WO-2007019427-A2 | METHODS AND COMPOSITIONS FOR PRESERVING THE VIABILITY OF PHOTORECEPTOR CELLS | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070032427-A1 | Methods and compositions for preserving the viability of photoreceptor cells | MASSACHUSETTS EYE AND EAR INFIRMARY | 2007-02-08 | — | — | US | disclosed |
| WO-2005105133-A2 | METHODS AND COMPOSITIONS FOR PRESERVING THE VIABILITY OF PHOTORECEPTOR CELLS | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2005-11-10 | — | — | WO | disclosed |
| US-20050129684-A1 | Methods and compositions for preserving the viability of photoreceptor cells | MASSACHUSETTS EYE AND EAR INFIRMARY | 2005-06-16 | — | — | US | disclosed |
| WO-2003061519-A2 | METHODS AND COMPOSITIONS FOR PRESERVING THE VIABILITY OF PHOTORECEPTOR CELLS | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2003-07-31 | — | — | WO | disclosed |
| US-20030105046-A1 | Interleukin converting enzyme (ICE) and central nervous system damage | THE GENERAL HOSPITAL CORPORATION | 2003-06-05 | — | — | US | disclosed |
| WO-1998057664-A9 | INTERLEUKIN CONVERTING ENZYME (ICE) AND CENTRAL NERVOUS SYSTEM DAMAGE | YUAN JUNYING (US) | 1999-04-08 | — | — | WO | disclosed |
| WO-1998057664-A1 | INTERLEUKIN CONVERTING ENZYME (ICE) AND CENTRAL NERVOUS SYSTEM DAMAGE | THE GENERAL HOSPITAL CORPORATION (US) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190216881-A1 | METHODS AND COMPOSITIONS FOR PRESERVING PHOTORECEPTOR AND RETINAL PIGMENT EPITHELIAL CELLS | ALDH1A2, PDE6B, PDE6C | CASP3 18/4885CASP7 69/4885CASP1 140/4885 |
| US-20190117724-A1 | METHODS FOR TREATING SPINAL CORD INJURY | NGF, GAP43, BDNF | CASP3 24/4885CASP7 45/4885CASP1 65/4885 |
| US-10799552-B2 | Methods for treating diabetic neurotherapy | NGF, NTRK2, BDNF | CASP3 22/4885CASP7 67/4885CASP1 46/4885 |
| US-10617735-B2 | Methods and compositions for preserving retinal ganglion cells | GAP43, PDE6C, NGF | CASP3 10/4885CASP7 24/4885CASP1 85/4885 |
| US-10639345-B2 | Compositions for preserving photoreceptor cells, retinal pigment epithelial cells, or visual function | ALDH1A2, PDE6B, PDE6A | CASP3 33/4885CASP7 139/4885CASP1 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.